P
11.05
0.21 (1.94%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Phathom Pharmaceuticals, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
-1.6
| 分析师共识 | NA |
| 内部交易活动 | -1.5 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -1.63 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.28% |
| 机构持股比例 | 84.77% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 30 Jun 2025 | 7,464,572 |
| Ensign Peak Advisors, Inc | 30 Jun 2025 | 2,519,972 |
| Catalys Pacific, Llc | 30 Jun 2025 | 1,167,114 |
| Avidity Partners Management Lp | 30 Jun 2025 | 1,064,500 |
| Gw&K Investment Management, Llc | 30 Jun 2025 | 1,048,472 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合